What to Know About Breast Implants (Consumer Update)
The FDA's plain-language consumer overview: breast implants are not lifetime devices, they carry known risks including systemic symptoms some call breast implant illness, and a signed patient decision checklist is required before surgery.
What this source says
The FDA explains that the life of implants varies and cannot be predicted, that risks include BIA-ALCL, capsular contracture, rupture, and systemic symptoms (BII), that a patient decision checklist must be received and signed before surgery, and that patients should follow monitoring instructions including MRI screening for silent rupture of silicone implants.
Why it matters
A short, readable starting point from the U.S. regulator — good for a first orientation before the more detailed pages.
Key findings
- “The life of breast implants varies by person and cannot be predicted” — additional surgeries may be needed.
- Known risks include BIA-ALCL, capsular contracture, rupture, and systemic symptoms (BII).
- A patient decision checklist must be received and signed before surgery.
- Follow monitoring instructions, report unusual symptoms, and use imaging (MRI for silicone silent rupture).
Limitations
A brief consumer overview, not a detailed clinical reference.
What this does not prove
It does not state that implants cause systemic symptoms or that any individual's symptoms are implant-related.
Source / citation
U.S. Food and Drug Administration (FDA) · Current as of January 31, 2025
https://www.fda.gov/consumers/consumer-updates/what-know-about-breast-implants
Last reviewed against the original source: 2026-09-02. Summaries are written in plain language; the original source is authoritative.
Breast Implant Illness Tracker provides education and organizational tools only and does not provide medical diagnosis or treatment.